Dr. Mastrangelo

Michael J. Mastrangelo, MD

Contact Dr. Mastrangelo

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
  2. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
  3. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma
  4. Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma. Comparison with Institutional Controls
  5. Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
  6. Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
  7. Intralesional therapy for in-transit and satellite metastases in melanoma
  8. Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
  9. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
  10. Altered drainage patterns in patients with melanoma and previous axillary dissection
  11. A pilot study of sunitinib malate in patients with metastatic uveal melanoma
  12. Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
  13. Lymph node ratio is an important and independent prognostic factor for patients with stage III melanoma
  14. Defining the critical hurdles in cancer immunotherapy
  15. Masthead
  16. Interleukin 10 in the tumor microenvironment: A target for anticancer immunotherapy
  17. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine
  18. In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2
  19. Conjunctival melanoma: Bladder and upper urinary tract metastases
  20. The wrath of RAFs: Rogue behavior of B-RAF kinase inhibitors